Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

USPTO allowance expands Enveric’s IP around non-hallucinogenic neuroplastogens targeting PTSD and other psychiatric and neurological conditions.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Allowed claims are expected to cover novel methylone-inspired neuroplastogenic compounds for potential treatment of post-traumatic stress disorder (PTSD) and other psychiatric disorders

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application covering novel compounds within its EVM401 Series of drug candidates. The EVM401 Series comprises proprietary, non-hallucinogenic mescaline-derived compounds designed to promote neuroplasticity for the potential treatment of psychiatric and neurological disorders.

The patent application, entitled "Substituted N-Propylamine Fused Heterocyclic Mescaline Derivatives," represents the third U.S. patent allowance within Enveric's EVM401 Series. Once issued, the patent is expected to strengthen the Company's growing intellectual property estate with composition-of-matter claims covering a unique series of proprietary, methylone-inspired benzodioxole analogs designed as non-hallucinogenic neuroplastogens for the potential treatment of PTSD and other psychiatric and neurological conditions.

“Building a robust intellectual property portfolio around differentiated neuroplastogenic compounds remains a central component of Enveric's strategy," said Joseph Tucker, Ph.D., Director and Chief Executive Officer of Enveric. “As recent clinical data reported by others in the literature continue to support further evaluation of methylone-based therapies for PTSD, we believe this latest patent allowance further strengthens the value of our EVM401 Series and our differentiated approach to developing proprietary mescaline-derived compounds that preserve key pharmacophoric features associated with methylone while introducing novel structural modifications designed to reduce or eliminate hallucinogenic effects.”

Unlike methylone, whose chemical structure resides in the public domain and lacks composition-of-matter patent protection, Enveric's proprietary analogs incorporate unique structural modifications to the benzodioxole ring that differentiate them from known molecules and allow for stronger intellectual property protection. In addition, these modifications may increase lipophilicity, facilitate penetration across the blood-brain barrier, and improve metabolic stability, offering the potential to support oral administration while preserving the neuroplastogenic profile.

About Enveric Biosciences

Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects. Enveric’s lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT_2A and 5-HT_1B receptors with the potential to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.

For more information, please visit www.enveric.com.

Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information, including, without limitation, statements regarding the expected issuance of the allowed patent application; the expected scope, strength, value or enforceability of any patent that may issue; Enveric’s intellectual property strategy; the potential therapeutic, neuroplastogenic, non-hallucinogenic, drug-like, blood-brain-barrier penetration, metabolic stability, oral administration or other properties of compounds in the EVM401 Series; the potential treatment of PTSD or other psychiatric or neurological disorders; the potential relevance of methylone-based therapies or third-party clinical data to Enveric’s development programs; and Enveric’s development plans, regulatory strategy and expectations regarding future preclinical or clinical studies.. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans," "expects" or "does not expect," "proposes," "budgets," "explores," "schedules," "seeks," "estimates," "forecasts," "intends," "anticipates" or "does not anticipate," or "believes," or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND application to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain sufficient future funding for product development, clinical development activities, working capital and other operating expenses on commercially reasonable terms, or at all; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric’s products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively.

A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission, including Enveric’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260915623266/en/

Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.com

Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
(646) 577-8520
cmcdonald@tiberend.com

Source: Enveric Biosciences

Key Terms

notice of allowance regulatory

A notice of allowance is an official confirmation from a patent office that a patent application has met all necessary requirements and is approved for granting. It signals that the invention is likely to receive legal protection soon, which can be important for investors considering the value and exclusivity of a new product or technology. Think of it as a green light indicating that the invention is on track to become legally protected.

uspto regulatory

United States Patent and Trademark Office (USPTO) is the federal agency that reviews and issues patents for inventions and registers trademarks for brand names and logos. For investors, USPTO decisions act like a gatekeeper for a company’s legal right to exclude competitors — similar to a property deed for ideas and brands — which can protect revenue, support pricing power, and affect a company’s long‑term value and risk profile.

composition-of-matter claims regulatory

Composition-of-matter claims are patent claims that cover the chemical structure of a specific molecule, compound, material, or mixture itself rather than a manufacturing process or a particular use. They grant the patent holder exclusive rights over the substance regardless of how it is made, like owning the recipe rather than just a cooking technique. For investors, these claims can create strong barriers to competitors and protect potential product revenue by preventing direct copies of the active substance.

lipophilicity technical

Lipophilicity is a chemical property that describes how strongly a molecule prefers to dissolve in fats or oils rather than in water, often expressed by measures like logP or logD. It influences how a drug or chemical moves through the body — affecting absorption, distribution, ability to cross cell membranes, and how it is formulated — so it matters to investors because it helps predict development challenges, dosing, and potential safety or regulatory issues.

blood-brain barrier medical

A protective barrier of tightly packed cells and supporting tissue that controls what substances in the blood can enter the brain, acting like a security checkpoint that keeps out most pathogens and many drugs while allowing essential nutrients through. For investors, the barrier matters because whether a therapy can cross or safely bypass it often determines clinical success, regulatory approval and commercial potential for treatments of brain disorders.